Microfluidics for personalized drug screening of cancer.

Microfluidics for personalized drug screening of cancer.
Curr Opin Pharmacol. 2019 Oct 18;48:155-161
Authors: Venugopal Menon N, Lim SB, Lim CT
Abstract
Resistance to targeted therapies is a major clinical challenge in cancer treatment. Despite technological advances, robust biomarkers or platforms predictive of treatment response are lacking owing to the inherent nature of complex genomic landscape of carcinoma. Nevertheless, recent efforts centred on performing direct drug screening on patient-derived cells through their ex vivo expansion and maintenance have enabled personalized stratification of treatment modalities. Microfluidics is one such technology that allows high-throughput drug screening through parallelization and automation using small-volume sample. In this review, we present recent microfluidic platforms that have been successfully applied for the maintenance and expansion of patient-derived tumor cells spanning diverse cancer types and sources (solid tumors or liquid biopsies (circulating tumor cells)) for personalized drug screening applications.
PMID: 31634805 [PubMed - as supplied by publisher]

Source: Current Opinion in Pharmacology - October 17, 2019 Category: Drugs & Pharmacology Authors: Venugopal Menon N, Lim SB, Lim CT Tags: Curr Opin Pharmacol Source Type: research